Methods of administering anti-tnf.alpha. antibodies

Details Methods of administering anti-tnf.alpha. antibodies Methods of administering anti-tnf.alpha. antibodies

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61K 31/519 (2006.01) A61M 5/178 (2006.01) C07K 16/24 (2006.01)

Patent

CA 2385745

Methods of treating disorders in which TFN.alpha. activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF.alpha. (e.g., K d = 10 -8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K off = 10 -3 sec-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

Affiliated with

Also associated with

Rating

Methods of administering anti-tnf.alpha. antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of administering anti-tnf.alpha. antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering anti-tnf.alpha. antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1351569